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Abstract
Multiple Sclerosis (MS) is an autoimmune disease that causes a myriad of symptoms,
including cognitive, sensory, and motor deficits, as well as gastrointestinal (GI) dysmotility. We
have previously demonstrated that male mice with experimental autoimmune encephalomyelitis
(EAE), the predominant model for MS, have disrupted GI motility, but the mechanisms for this
dysmotility are not understood, and potential sex differences have not been evaluated. Since 5hydroxytryptamine (5-HT; serotonin) is a mediator of motor and secretory reflexes in the gut, we
investigated key elements of mucosal 5-HT signaling in the EAE mouse model of MS. Enzyme
linked immunosorbent assay (ELISA) was used to evaluate 5-HT tissue levels as normalized by a
bicinchoninic acid assay and RT-qPCR was used to evaluate mRNA expression for the rate
limiting molecule in 5-HT synthesis, tryptophan hydroxylase 1 (Tph1), and the serotonin reuptake
transporter (SERT), both of which were normalized to the housekeeping gene beta 2 microglobulin
(B2M). Motility and fecal composition were also compared in female versus male mice with EAE.
The mRNA expression for Tph1 was decreased in EAE mice, but levels of 5-HT in the tissue and
SERT mRNA expression were unchanged. Furthermore, no differences were detected in colonic
motility, fecal water content, or whole GI transit in female versus male mice with EAE. However,
it was noted that male mice with EAE displayed peak GI dysfunction at day 21, whereas female
mice with EAE showed peak GI dysfunction at day 27. These findings indicate that female and
male mice present with similar levels of GI dysfunction over time, representing comparable
models for motility disruption in EAE, and suggest that mechanisms other than altered 5-HT
signaling are responsible for altered motility in this model.
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Introduction
Multiple Sclerosis and GI Dysfunction
Multiple Sclerosis (MS) is typically characterized as an inflammatory autoimmune disease
of the central nervous system (CNS) in which T cells attack the myelin sheaths of axons resulting
in scar tissue, sclerosis, and nerve fiber damage. This damage and loss of myelin creates a
disruption of nerve signals resulting in a wide expanse of symptoms including movement
disabilities (National Multiple Sclerosis Society, 2018). An overlooked component of these
movement disabilities includes gastrointestinal (GI) motility, as up to two thirds of all MS patients
report having bowel dysfunction, with constipation and fecal incontinence being the predominant
symptoms (Future, Joy, & Richard B. Johnston, 2001; Levinthal et al., 2013; Preziosi et al., 2013).
A recent report stated that approximately fifty percent of individuals with MS will experience
constipation, with thirty percent of the MS population also experiencing fecal incontinence (Future
et al., 2001). Despite the common prevalence of these symptoms and general GI dysfunction in
the MS population, the exact etiology behind this dysfunction is still unclear.
A prominent experimental approach in attempting to understand these mechanisms is
derived from the use of the experimental autoimmune encephalomyelitis (EAE) mouse model of
MS. To this extent, a recent study by the Mawe laboratory (Spear et al., 2018) showed that male
mice with EAE demonstrate altered GI function consistent with MS-related constipation,
validating the model as a potential means of examining the molecular changes that might occur
leading to the noted alterations in GI function. Furthermore, recent studies have indicated the
involvement of the enteric nervous system (ENS) as a target of circulating auto-antibodies in MS
and EAE (Spear et al., 2018; Wunsch et al., 2017). The ENS is the neuronal governing system of
GI tract motor and secretory functions, and consists of cellular aspects and proteins that are similar
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to those of the CNS. In this regard, the studies by the Mawe and Kürten labs (Spear et al., 2018;
Wunsch et al., 2017) indicated that there is an involvement of autoantibodies in MS, which targets
the neurons and glial cells of the ENS, similar to those that target the CNS, and might mediate
components associated with GI dysfunction. However, despite these breakthrough findings, the
exact neuronal mechanisms that lead to the alterations in motility are still unknown.

The Role of Serotonin in GI Motility
One possible mechanism leading to the alterations in MS-related GI motility involves the
role of serotonin. Serotonin (5-hydroxytryptamine; 5-HT) is an intercellular signaling molecule
that initiates, regulates, and modifies GI motility, secretion, and vasodilation (Spohn & Mawe,
2017). The majority of 5-HT in the body is synthesized in the GI tract, with a subtype of
enteroendocrine cell, the enterochromaffin cell, being the primary source of 5-HT.
Enterochromaffin cells function as sensory transducers and use the rate limiting molecule
tryptophan hydroxylase 1 (Tph1) to initiate the synthesis of L-tryptophan to 5-HT. Unlike
acetylcholine, 5-HT does not have a counterpart intercellular degrative enzyme to terminate
signaling, and thus requires a specialized transport molecule, serotonin selective reuptake
transporter (SERT), to remove 5-HT from the intercellular space and stop receptor activation. Once
it is transported, 5-HT can be recycled into vesicles or degraded by monoamine oxidase (Mawe &
Hoffman, 2013).
Serotonin signaling has been investigated in animal models of GI inflammatory diseases
and in human samples from ulcerative colitis and diverticulitis patients. An alteration consistent
in these conditions is decreased epithelial expression of SERT with the exact 5-HT signaling
pathway alterations varying for each disease (Coates et al., 2017). As MS is associated with
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inflammation, it stands to reason that a contributing factor of this inflammation and GI dysfunction
could correspond to altered levels of 5-HT and SERT. This is supported by preliminary data from
the Mawe lab examining 5-HT levels outside the epithelium in colon preparations of EAE versus
control mice using amperometry. In these experiments, 5-HT was measured at the mucosal surface.
These findings showed that there was a significantly higher concentration of 5-HT measured at the
mucosal surface of colons from the EAE mice (figure 1 A), and that this difference was eliminated
in the presence of fluoxetine, a SERT inhibitor (figure 1 B). These data suggest an alteration of 5HT signaling in EAE in correlation to a decreased expression and/or function of SERT. Based on
this preliminary data and previous literature it could be suggested that an alteration in 5-HT
mechanisms might be associated with the GI dysfunction exhibited by the EAE model. This led to
the hypothesis that there is an increase in 5-HT availability in the EAE GI tract driven by a
decrease in the 5-HT transporter SERT.
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Sex Differences in Multiple Sclerosis/EAE
As previously mentioned, it has been validated that the EAE model demonstrates GI
dysmotility consistent with that of MS (Spear et al., 2018; Wunsch et al., 2017). However, the
strains of mice selected and sex of the animals used for studies have varied across experiments,
yielding slightly different results in susceptibility to EAE depending on these variables
(Constantinescu et al., 2011). This is somewhat consistent with the general heterogeneric nature
of MS as a whole and its sexually dimorphic characteristics. In fact, the EAE model has been
utilized to examine sex differences in disease presentation of MS (Spach et al., 2009; Teuscher et
al., 2004, 2006). These studies have shown that there is both an involvement of the Y chromosome
as well as an age dependent factor in disease susceptibility in the model (Spach et al., 2009;
Teuscher et al., 2006). Similarly, investigations along these lines have indicated that the sex of the
mouse is the strongest contributing factor in the development of the hallmark brain and spinal cord
lesions associated with EAE when also taking into consideration the age of the mouse and season
of induction of the disease (Teuscher et al., 2004). Despite this critical investigation into possible
sex differences within the EAE model, most of the work to date has focused on differences within
the CNS derived symptomology of EAE and does not indicate whether or not these differences in
susceptibility and effectiveness as a model might exist in the ENS, specifically in terms of
modeling GI dysmotility.
That said, previous data from the Mawe lab has predominately focused on the use of male
mice. This focus was derived from the fact that male mice in the hands of the Mawe lab have
demonstrated a high rate of consistent EAE disease presentation in terms of characteristic motor
symptoms ranging from tail weakness to quadriplegic status and have therefore been most
associated with GI dysfunction, whereas female mice tend to classify as asymptomatic. Despite
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this, preliminary data from the Mawe lab has shown that female mice reported to be largely
asymptomatic, or did not develop severe motor symptoms, still showed altered fecal water content
(figure 2 A), which would be consistent with GI dysfunction. These data appear to indicate that GI
symptoms can be associated with mice that present as asymptomatic, as do most female mice in
the Mawe lab studies, supporting the idea that female and male mice could represent comparable
MS GI dysmotility models despite the apparent difference in EAE susceptibility between the two
sexes.
Further supporting this possibility, a population of asymptomatic male mice in a recent
study by the Mawe lab showed that there was an increase in colonic transit time (slower motility)
measured using the bead expulsion assay (figure 2 B) and therefore could be classified as having
altered GI motility despite presenting without the classical EAE motor symptoms. Collectively,
however, these data were not strong enough to conclude that asymptomatic mice will exhibit GI
dysfunction, as there is still a strong correlation between an increase in motor symptom severity
and GI dysfunction. This leaves much to speculation as to whether or not mice that are
asymptomatic, such as the female population used in the Mawe lab, actually develop GI
dysfunction comparable to the symptomatic male mice. Therefore, based on these preliminary
data, we tested the hypothesis that female mice can in fact serve as comparable models to their
male counterparts in terms of displaying GI dysfunction consistent to that of MS.
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Study Aims
As can be seen from gaps in the literature, there is still much to be discovered in terms of
the implications between the ENS and MS and the impact on GI dysfunction. In this regard, it is
the goal of this study to contribute to the field by providing a novel assessment on the role of
mucosal 5-HT signaling within the EAE GI tract and the potential sex differences in GI motility
of EAE mice. This assessment was accomplished through both molecular and in vivo motility
assays. The molecular assays, including RT-qPCR to examine Tph1 and SERT mRNA expression
and an enzyme-linked immunosorbent assay (ELISA) to assess the tissue 5-HT content, were
utilized to fulfil the goal of examining key elements of 5-HT signaling. In parallel, the in vivo GI
motility assays, including an analysis of colonic motility as assessed by bead expulsion,
constipation as measured by fecal water content, and an examination of whole GI transit, allowed
for an assessment into the GI motor activity of both female and male mice.
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Methods
Animals
For the in vivo GI motility assays used in this study, two cohorts of female and male
C57BL/6J mice approximately 8 weeks of age were utilized. The first cohort of mice were obtained
from within the Sox10/GCAMP transgenic C57BL/6J mouse line of the Mawe lab mouse colony
and consisted of 26 mice (14 EAE and 12 controls, which comprised of 7 EAE female/males and
6 control female/males). Similarly, the second cohort of mice were C57BL/6J mice purchased
from Jackson Labs, Bar Harbor, ME, and had a total of 38 mice (19 EAE and 19 controls, which
comprised of 9 female controls, 10 male controls, 10 female EAE, and 9 male EAE). All
experimental animal protocols used for this study were approved by University of Vermont
Institutional Animal Care and Use Committee.

EAE Induction
Female and male C57BL/6J mice were randomly divided into control and experimental
condition groups. The experimental conditioned mice were induced with EAE using the 2X MOG
protocol, as follows. Mice were immunized with a sonicated emulsion of myelin oligodendrocyte
glycoprotein peptide (MOG35-55) and complete Freund’s adjuvant (CFA) containing 200 μg
Mycobacterium tuberculosis H37RA (Becton Dickinson & Co). The mice then underwent a 2X
induction protocol, in which they received two posterior right and left flank subcutaneous
injections of the emulsion each a week apart with the second injection being anterior to the initial
injection site as previously described (Spear et al., 2018). The control mice followed the same
protocol, however they only received CFA injections. Daily evaluations included recordings of
weight and disease severity scores beginning 14 days postimmunization until the end of the trial
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on day 28 as previously described (Spear et al., 2018). EAE disease scoring was based off of a 0
to 5 scale in which a 0 was asymptomatic, 1 was tail paralysis, 2 was tail paralysis and hind limb
weakness, 3 was tail and hind limb paralysis, 4 was tail and hind limb paralysis and urinary
incontinence, and 5 was moribund. Once a mouse reached a score of 3, food pellets and Napa
Nectar were placed at the bottom of the cage to assure nutrient uptake. Fluid injections were also
given to mice if they were noted to have lost 30 percent of their initial body weight, mice that
consistently lost weight at this percentage and did not respond to fluid injections were euthanized.
Cumulative disease scores were calculated by adding together the daily somatic disease scores
across the span of the experiment to represent the total disease score accrued.

GI Motility Assays
Three assays were utilized to assess in vivo GI motility: bead expulsion, fecal output and
water content, and an evaluation of whole GI transit. Bead expulsion and fecal water content were
conducted both as a baseline measure on day 0 before induction of EAE as well as an experimental
measure, whereas the whole GI transit was only conducted as an experimental measure. All
motility assays were completed by day 28 of the experiment, with the fecal water and bead
expulsion assays occurring on day 27 and the whole GI transit assay occurring on day 28. The
second cohort of mice also underwent an additional GI motility time point assessment at day 21.

Bead Expulsion
The bead expulsion assay was utilized to assess colonic transit time. Mice were lightly
anesthetized with isoflurane and a 2.3 mm bead was inserted approximately 20 mm into the distal
colon using a blunt gavage needle. Time of bead insertion, time of recovery from anesthesia, and
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time of bead expulsion were all recorded, allowing for an assessment of total colonic transit time
as measured by the time elapsed between insertion and bead expulsion. This assay was conducted
as a baseline measure before the induction of EAE and as an experimental measure at day 27 to
allow for a comparison in terms of progression of symptoms. The second cohort of mice also
underwent another time point assessment, in addition to the one at day 27, at day 21 to allow for a
more in-depth analysis of colonic motility during the disease course.

Fecal Water Content
Each mouse was placed in an individual cage and monitored for 1 hour. During this time,
deposited fecal pellets were collected and weighed. The pellets were then dried for a period of 24
hours at 50◦C and reweighed to allow for a calculation of fecal water content. The number of pellets
was also recorded in order to better understand the changes in motility. This assay was conducted
as a baseline measure before the induction of EAE and as an experimental measure at day 27. The
second cohort of mice also underwent another time point assessment, in addition to the one at day
27, at day 21 to allow for a more in-depth analysis of potential GI dysmotility during the EAE
disease course.

Whole GI Transit
Mice were placed in individual cages without bedding and administered an oral gavage of
300 μl 6% carmine red and 0.5% methylcellulose (Sigma Aldrich) in water. They were then given
food and water ad libitum and monitored until carmine red was noted in the fecal pellets, indicating
the total time elapsed for whole GI transit to occur.
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Tissue Collection
After completion of the 28-day experimental period following previous Mawe lab
procedures, the mice were euthanatized and their colons dissected and separated into six segments
for potential use in molecular analysis.

Examination of 5-HT Signaling
For the purpose of this portion of the study previously obtained EAE and control colon
segments from C57BL/6J were utilized. These colon segments were stored at -80◦C and originated
from experiments related to the Spear et al. study, following the 2X MOG protocol. Key aspects
of 5-HT signaling were assessed including mRNA expression of the synthetic enzyme, tryptophan
hydroxylase 1 (Tph1), and serotonin selective reuptake transporter (SERT) using RT-qPCR, as
well as tissue 5-HT content using an enzyme-linked immunosorbent assay (ELISA).

RT-qPCR
For the purpose of this study RT-qPCR was utilized in order to examine the mRNA
expression of 5-HT, as measured by Tph1 and SERT (primers obtained from Thermofisher). RNA
was extracted from colon preparations using a RNeasy Mini Kit (Qiagen) and analyzed using a
NanoDrop Spectrophotometer in the COBRE laboratory. Samples then underwent RT-PCR to
convert the isolated RNA to stable cDNA for use in qPCR experiments. All qPCR experiments
were conducted using Applied Biosystems 7500 Fast Real-Time PCR System under Standard 7500
Mode in the COBRE laboratory, therefore yielding a quantification of mRNA expression of Tph1
and SERT in EAE samples relative to control samples. These data were then normalized to a
selected housekeeper gene, beta 2 microglobulin (B2M), that demonstrated no significant
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difference between the groups despite experimental condition, allowing for a more accurate
analysis of mRNA expression between groups.

ELISA
A 5-HT ELISA kit (Beckman Coulter) was used to directly examine the tissue 5-HT
content in the GI tract of EAE versus control mice as quantified by the microplate reader in the
COBRE laboratory and standardized using a known concentration serotonin solution ranging from
0 nM – 200 nM. These data were then normalized to the total amount of protein present in the
samples through use of bicinchoninic acid assay with the Pierce BCA kit (Thermofisher).

Statistical Analysis
All statistical analysis was completed using GraphPad Prism for Windows 7. Data were
analyzed using an unpaired t test in order to determine statistical significance. Additionally,
outliers were identified and excluded from the data sets using a Q test (2 standard deviations from
the mean). Statistical significance is denoted as * P <0.05, ** P <0.01, *** P <0.001, and **** P
<0.0001.
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Results
Female and male mice have similar disease score characteristics
Cumulative disease score was obtained through an addition of the daily somatic disease
scores across the total experimental period, allowing for an illustration of the total disease severity.
There was no significant difference between the female EAE and male EAE cumulative disease
scores in either the first or second cohort of mice (figure 3). These data suggests that both female
and male EAE mice establish a similar degree of disease severity across the experimental period.
The day of disease onset was determined based on the first experimental day that a score
other than 0, asymptomatic, was recorded. There was no significant difference between female and
male EAE mice in the day of disease onset for either the first or second cohort (figure 4). These
data suggest that female and male EAE mice have a similar systemic disease onset time course as
measured by the EAE scoring protocol.
Average daily disease scores across the experimental period were examined in order to
investigate the potential differences in disease activity for female and male mice. Visually the
disease activity was closely mirrored between female and male mice in both cohorts (figure 5 A
& B), with the caveat that female mice in the second cohort presented with disease activity that
was generally slightly less severe than male mice (figure 5 B). Additionally, male mice were shown
to have a slightly higher average daily disease score than female mice around experimental day 21
in both cohorts (figure 5 A & B). In contrast, female mice were shown to have a slightly higher
average daily disease score than males on experimental day 17 and 18 for the first and second
cohort respectively (figure 5 A & B). However, analysis of these individual time points shows no
significant difference between female and male daily disease activity (figure 5 C - F). Taken
together these data suggest that female and male mice have similar general daily disease activity.
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Female and male mice represent comparable GI motility models
Bead expulsion, fecal water content, and whole GI transit were all utilized to assess the
possibility of sex derived motility differences in the EAE mouse model. Bead expulsion allowed
for an assessment of colonic motility, measured through the time elapsed between bead insertion
and expulsion. As previously demonstrated by experiments in the Mawe lab, bead expulsion on
experimental day 27 for the combined EAE female and male mice was shown to be significantly
slower than control mice for both cohort one, P = 0.0268, and cohort two, P = 0. 0037 (figure 6),
signifying delayed colonic motility in EAE mice. However, no significant difference was noted
amongst both studied cohorts of mice when comparing female EAE to male EAE mice (figure 7).
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These data suggest that both female and male mice exhibit comparable levels of GI dysfunction in
terms of decreased colonic transit time.
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Fecal water content was also used as a measure of GI dysfunction through an assessment
of constipation, in that a smaller percentage of water indicates drier fecal pellets consistent with
constipation. For this particular assay, the first and second cohort results for the combined female
and male EAE mice as opposed to the controls presented differently. Consistent with the previous
experiments from the Mawe lab, the EAE mice in the first cohort demonstrated a significant
decrease in water content as compared to controls, P = 0.0444 (figure 8 A), whereas, the second
cohort showed no significant difference between the control and EAE mice (figure 8 B). These
data suggest that the first cohort of EAE mice showed GI dysfunction consistent with constipation
while the second cohort of EAE mice did not present with decreased fecal water content. When
examined by sex, it was found that there was no significant difference between the female EAE
and male EAE mice across both cohorts (figure 9). These data then suggest that both female and
male EAE mice present with the comparable levels of GI dysfunction to one another.
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Finally, whole GI transit, as measured by the time after oral gavage of carmine red dye to
the presence of the dye within the fecal pellets, was noted to not be significantly different in either
cohort when examining the total female and male EAE mice as compared to control mice (figure
10 A & C). These data would suggest that for these two cohorts of mice, at the time point that was
studied, GI dysfunction did not reach an extent of decreased whole GI transit as has been
previously seen in experiments by the Mawe lab. Additionally, there was no significant difference
noted between the first cohort of female EAE versus male EAE mice in terms of whole GI transit
time (figure 10 B). In contrast, the second cohort of female EAE versus male EAE mice that
showed a slower whole GI transit in female EAE mice as opposed to males (figure 10 D). In this
regard, the data from the first cohort of mice suggests that both female and male EAE mice present
with a comparable degree of GI dysfunction. However, the data from the second cohort of mice
suggests that female EAE mice have a slower GI transit time than males, presenting a possible sex
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derived difference in the model, the implications of which will be discussed in greater detail
bellow.

Female and male mice have different peak colonic dysmotility time points
As mentioned previously, colonic motility was assessed using bead expulsion. For the
second cohort of mice two separate time points, 21 and 27 days into the experimental protocol,
were utilized in order to assess the level of colonic dysmotility, spurred by separate concurrent
experimentation in the Mawe lab which will be discussed in greater detail bellow. Bead expulsion
at day 21 showed a significant increase, P = 0.0411, in expulsion time for male EAE mice as
opposed to male control mice (figure 11 B), indicating slowed colonic motility and GI dysfunction.
This is in contrast to the female EAE and control mice which did not significantly differ from each
other on day 21 (figure 11 A). Bead expulsion at day 27 showed a significant increase, P = 0.006,
in expulsion time for female EAE mice as opposed to female control mice (figure 11 C), indicating
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slowed colonic motility and GI dysfunction. These data at day 27 are in contrast with the male
EAE and control mice which did not significantly differ from each other at the selected time point
(figure 11 D). Taken together the bead expulsion data from day 21 and day 27 suggest that female
and male EAE mice differ in the peak onset of GI dysfunction, with male EAE mice most
prominently presenting with slowed colonic motility at day 21 and female EAE mice
predominantly presenting with slowed colonic motility at day 27.

22
Altered GI motility is not directly tied to changes in 5-HT signaling
To assess the role of 5-HT in GI dysfunction of EAE mice, molecular assays were utilized
to examine mucosal 5-HT signaling in various stages including mRNA expression for critical 5HT signaling molecules and for and tissue 5-HT content. RT-qPCR was utilized to assess the
mRNA expression of serotonin selective reuptake transporter (SERT) and the synthetic enzyme,
tryptophan hydroxylase 1 (Tph1) to elucidate an understanding of 5-HT mRNA expression.
mRNA expression was normalized to the housekeeper gene beta 2 microglobulin (B2M), as this
gene showed no significant difference between both the experimental and control conditions. Final
analysis showed that there was a significant, albeit modest, decrease in Tph1 expression between
EAE and control mice, P = 0.046 (figure 12 A); however, there was no significant difference in
SERT expression between EAE and control mice (figure 12 B). These data indicate that there is a
potential alteration in 5-HT synthesis, due to the decrease in Tph1 expression, however this is not
mirrored in the expression of SERT, suggesting that any possible changes to the 5-HT pathway
would not be mediated by SERT.
Tissue 5-HT content was assessed using an enzyme-linked immunosorbent assay (ELISA)
and the obtained data was normalized against the total quantity of proteins present in the tissue, as
determined by a bicinchoninic acid assay. These data showed that there was no significant
difference in tissue 5-HT content in EAE mice as compared to controls (figure 13). Taken together
with the data from the RT-qPCR assay, these data suggest that the dysmotility noted in the EAE
model is not driven through alterations in 5-HT signaling.
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Discussion
This study aimed to gain a deeper understanding of the involvement of the ENS in GI
dysfunction in the EAE mouse model of MS, specifically examining the role of mucosal 5-HT
signaling and the potential sex derived motor activity differences within the model. The findings
presented suggest that the alterations in GI motility seen in the EAE model are not driven by
changes to mucosal 5-HT signaling. Additionally, the results demonstrated that both female and
male EAE mice induced under the 2X MOG protocol present with similar extents of GI
dysfunction though the time course of said dysfunction differs by 6 days between the sexes.

Female and male mice can both serve as models of MS-related GI dysfunction
As mentioned previously, many studies utilizing the EAE mouse model of MS have
differed in the use of the selected strain, sex, and method of EAE induction. The Mawe lab is no
exception to this claim, as most of the EAE studies completed have predominately utilized male
mice, as they were previously shown to be most consistent in demonstrating EAE symptomology
and are therefore thought to be the ideal model for assessments of GI dysfunction. However, this
study suggests that female and male EAE C57BL/6J mice induced utilizing the 2X MOG protocol
are comparable models in terms of the extent of presented GI dysfunction based upon the in vivo
assays as well as the disease activity characteristics and can therefore be used in conjunction with
one another. These findings then alter the paradigm for the selected use of one sex over the other
to model GI dysfunction in MS.
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Multiple time point analysis
While the results of this study suggest that female and male mice represent comparable
models , these findings also suggest that there are transient differences between the two sexes.
Most notably the discovery that female and male mice have differing peak time points for colonic
dysmotility as analyzed by bead expulsion. As previously mentioned, these findings were spurred
by separate concurrent research in the Mawe lab. This separate experimentation was designed with
the purpose of discovering the optimal experimental time course to examine consistent GI
dysfunction under the 2X MOG induction method of EAE in male mice. Data from that
experimentation revealed that colonic dysmotility could be noted at day 21, which was earlier than
the previously utilized time point in the Mawe lab (data not shown). Following this trend of data,
the new checkpoint was added to the second cohort of mice with the expectation that there would
be notable colonic dysmotility in males on day 21. As this concurrent investigation utilized only
male mice however, the motility outcome for female mice was unknown. The finding that female
and male mice differ in peak colonic dysmotility added a new aspect to the analysis of potential
sex derived differences in the motor activity of EAE mice. This once again shifts the paradigm and
understanding of the utilization of the EAE mouse model for examination of GI dysmotility. While
it can be said that these models are comparable to one another based on the fact that no significant
difference was noted between the selected in vivo assays and can therefore be used in conjunction
with one another, it cannot be discounted that there are still possible mechanistic differences
between the two sexes as evidenced by this difference in peak colonic dysmotility time points.
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Differences in in vivo motility assays
Whole GI transit
Previous studies by the Mawe lab, specifically reported in Spear et al., demonstrated that
EAE mice present with delayed whole GI transit, however these findings were not mirrored in this
study at the selected time point analysis. This difference between these two studies is most likely
derived from mechanisms concerning gastric emptying. As shown in Spear et al. it has been
suggested that EAE mice present with accelerated gastric emptying and no changes in small
intestinal motility in relation to control mice (Spear et al., 2018). In turn, based on these findings
it is possible that an increase in gastric emptying without a change in small intestinal motility could
compensate for a reduction in colonic motility, resulting in a whole GI transit that is not
significantly different from the controls, as was seen in this study.
Similarly, the fact that female EAE mice had a significantly slower whole GI transit than
male EAE mice in the second cohort again implicates the suggested time component difference of
GI motor activity between female and male EAE mice. As was suggested by the findings of the
bead expulsion assay, female mice experience peak colonic dysmotility at day 27 as opposed to
males which experience peak colonic dysmotility at day 21. Since the whole GI transit assay is
conducted at day 28, only one day after the stated peak colonic dysmotility time point for females,
it stands to reason that female mice would have a slower GI transit time compared to males. This
could be explained through the mechanism that the noted increased gastric emptying in EAE mice
might not be able to compensate as strongly for the greater extent of delayed colonic motility seen
in females as compared to males. While this difference does exist between female and male mice
in the second cohort for whole GI transit, the general results of the assay are unchanged. Female
mice when compared to their respective controls show no significant difference in whole GI transit,
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nor do males against their respective controls, leading to the general reported nonsignificant results
of the assay. Additionally, these findings in conjunction with the difference in peak colonic
motility time points suggest that there might be alterations in the molecular underpinnings of the
2X MOG EAE model between female and male mice, however these differences do not impact
the general results of the in vivo motility assays allowing for both sexes to serve as comparable
models.

Fecal water content
Previous results concerning fecal water content of EAE mice have generally shown a
smaller percentage of water content in EAE mice than controls. These findings suggest that EAE
mice tend to have alterations in secretion and absorption in conjunction to the noted dysmotility
features (Spear et al., 2018). However, the results from the current study in terms of fecal water
content are much more dichotomized between the two cohorts for the total EAE and control groups
of mice. In this sense, the first cohort of mice is consistent with the previously conducted studies
by the Mawe lab, however the second cohort presents a different story. The results from the second
cohort suggest that there is not a difference in the levels of absorption or secretion within the GI
tract between EAE and control mice. However, these findings also need to be examined in
conjunction to the assessment of colonic motility through bead expulsion. These data show that
for the selected time point, day 27, there is a significant difference between the total EAE and
control groups, indicating that there is colonic dysmotility present within the EAE group.
Therefore, the findings of the fecal water content assay indicate that for that the second cohort of
mice, the mice presented with colonic dysmotility without alterations to secretion and absorption.
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Variability of data from EAE models
While the variability of EAE presentation between the sexes and strains of mice has been
commonly recognized in the literature, there has also been noted to be a level of variability in EAE
presentation and GI dysfunction from experiment to experiment as well as between studies
utilizing the same induction method. This particular phenomenon was noted in this current study,
as was just mentioned in the fecal water content assays, as well as when comparing this study to
previous investigations in the Mawe lab utilizing the 2X MOG induction protocol. These
variability differences are most likely derived from the complexity of EAE pathogenesis. It is
currently thought that the EAE mechanism for the MOG protocol involves the activation of the
immune system, through the foreign presentation of MOG. This immune response, specifically the
activated T cells primed against MOG, then enter the CNS and cause the destruction of myelin,
due to the presence of the MOG peptide. In turn, the effects of the immune response cause the
production of antibodies by B cells which can interact with enteric neurons and glial mediating the
GI dysfunction observed in the model, as was supported by Spear et al., that showed that B cell
deficient EAE mice did not demonstrate altered GI motility (Spear et al., 2018). It is from this
multitude of processes involved in EAE pathogenesis that many levels of variability can exist,
purely based on immune system signaling, regulation, and response to the MOG induction,
creating the possibility of differing extents of disease severity and GI dysfunction while utilizing
the same experimental protocol.
Similarly, for female mice in particular, the stage of the estrous cycle can impact the
presentation of EAE severity and symptomology. A recent study suggested that female mice in
proestrus, the stage of the estrus cycle characterized by an elevated expression of estrogen and
progesterone, demonstrated attenuated EAE symptomology as induced using MOG, both in terms

29
of disease score and neurological motor impairment. Likewise, the same study reported that the
administration of CFA or an emulsion of CFA and MOG had a tendency to prolong the amount of
time spent in diestrus, therefore altering the timing of the normal estrous cycle (Rahn, Iannitti,
Donahue, & Taylor, 2014). Viewed together, these findings implicate the role of the estrous cycle
on EAE variability, as desynchrony in the estrous cycle between females could alter individual
EAE disease presentation and impact the obtained experimental data.
On a more environmental level however, the involvement of the gut microbiome has also
been implicated in EAE susceptibility and severity (Chu et al., 2018). That said, it is well known
that the gut microbiome also has a predominant influence on GI activity. Taken together, these
factors suggest that separate cohorts of mice could respond differently to an induction of EAE
depending on the expression of bacteria within their GI tract, even if they are from the same strain
of mice, demonstrating another potential avenue for variability of data from EAE models.

5-HT signaling and the search for a stable housekeeper gene
While alterations in 5-HT signaling have been implicated in various GI inflammatory
diseases, including ulcerative colitis and diverticulitis (Coates et al., 2017), the current study
suggests that changes in mucosal 5-HT signaling are not a causal agent behind the reported GI
dysfunction in the EAE mouse model of MS. This assessment was primarily obtained through the
use of RT-qPCR as this allowed for an mRNA derived analysis of SERT, which was the
hypothesized driving force behind the possible alterations in 5-HT signaling and has been
confirmed to be altered in the previously mentioned GI inflammatory diseases.
The caveat to the use of RT-qPCR in this study however, was the ability to find a stable
housekeeper gene which could be used to normalize the results between both the EAE and control
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conditions. Previous experimentation in the Mawe lab has commonly relied on the use of
hypoxanthine phosphoribosyltransferase (HPRT) and ubiquitin (UBC) as the housekeeper genes,
since both of these genes have been shown to be stable between the different conditions. However,
when these genes were tested for this particular study there was a significant decrease in the mRNA
expression for both HPRT and UBC in EAE mice, negating their use for normalizing RT-qPCR
data in the current study. An in-depth literature search was conducted in order to determine other
possible suitable housekeeper genes. As very little work has been completed utilizing RT-qPCR
to examine mRNA expression in EAE colon tissue, the chosen reviews by Eissa et al. focused on
RT-qPCR in inflamed colonic tissue from the mouse model of colitis, as this model would
hypothetically be similar to the GI inflammation and dysmotility in EAE mice (Eissa et al., 2016;
Eissa, Kermarrec, Hussein, Bernstein, & Ghia, 2017). From these reviews, as well as previous
Mawe lab experimentation, six other possible housekeeper genes were selected as potential
candidates. These genes included 18s ribosomal RNA, eukaryotic translation elongation factor 2
(Eef2), phosphomannomutase 1 (PMM1), TATA-box binding protein (Tbp), glucuronidase beta
(Gusb), and beta 2 microglobulin (B2M). Of these tested genes, only B2M was shown to have no
significant difference between the EAE and control group. All other tested genes demonstrated a
significant decrease in mRNA expression of the selected gene in EAE samples as compared to
controls (data not shown). This appears to indicate that there might be a mechanism of molecular
degradation that is higher or altered in EAE mice as compared to controls, leading to this trend.
Therefore, a more thorough analysis of RT-qPCR techniques utilizing EAE colon tissue is needed
in order to better understand future applications of RT-qPCR in EAE derived samples and to
determine the ideal housekeeper gene for EAE colonic tissue.
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Choice of statistical analysis
The statistical analysis and conclusions for this study were possible due to the ability to
examine the data in a sub-grouped manner, examining both the total EAE and control populations
as well as the specific subsets of female and male EAE and control mice. It can be recognized that
at a glance there could be issues with the selected sub-grouped methodology instead of looking at
all four data sets (female EAE, female control, male EAE and male control) as a whole entity using
a two-way ANOVA following statistical conventions. However, this study was designed with
purpose of determining the possible differences between two specific groups, female and male
EAE mice, therefore justifying the separation of data analysis.

Future directions
Deeper examination of 5-HT signaling
As mentioned previously, this study’s design relied on an examination of mRNA
expression to ascertain possible alterations in SERT. However, this analysis method only allowed
for an indirect evaluation of the SERT mechanism and its involvement in 5-HT signaling. In this
sense, it is possible that there are alterations in the protein level, post translational modifications,
or protein function of SERT which could corroborate with the amperometry preliminary data seen
in the Mawe lab, in which addition of a SERT inhibitor normalized 5-HT release between EAE
and control tissue. Therefore, a functional study of SERT changes is necessary in order to better
understand the true implications behind the involvement of SERT in mucosal 5-HT signaling in
the EAE model.
Likewise, the results from this study concerning the decreased mRNA expression of Tph1
also provides an area of future study. 5-HT is synthesized in enterochromaffin cells which use the
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rate limiting enzyme Tph1 to convert L-tryptophan to 5-HT (Mawe & Hoffman, 2013). In this
sense, an analysis of enterochromaffin cells would provide insight into a possible explanation as
to why this study found that there was a decrease in Tph1 mRNA expression without any noted
alterations to tissue 5-HT content. One possible avenue for exploration would include the use of
immunohistochemistry to stain enterochromaffin cells utilizing a goat anti-5-HT polyclonal
antibody labeled with donkey anti-goat Cy3 as previously described (Hoffman et al., 2012). These
stained cells could then be manually counted based on numbers of cells per colonic gland as
previously described (Linden et al., 2005), allowing for an assessment in the prevalence of
enterochromaffin cells for 5-HT synthesis. The potential of including this work as a future aim in
studies has already been discussed in the Mawe lab.

Sex derived difference experimentation
The difference in findings between cohorts for in vivo GI motility assays demonstrated in
this study alludes to the concept that there are transient effects in examining GI dysfunction within
the EAE model using the 2X MOG protocol. Both of these two cohorts were induced under the
same protocol and followed the same time course assessment, with the exception of an additional
time point for bead expulsion and fecal water content at day 21 utilized for the second cohort.
However, despite this similarity in protocol there are differences between the two cohorts in terms
of reported significance of the results, the possible reasoning behind this being previously
addressed. Similarly, the fact that this current study failed to replicate the results for whole GI
transit as was seen in Spear et al. utilizing the same strain of mice, induction method, and time
course again illustrates the transient nature of GI symptoms in the 2X MOG EAE model. Taken
together, it is therefore suggested that future studies explore the possible sex differences in motor

33
activity in a more consistently robust induction method of the EAE model in terms of GI
dysfunction in order to truly ascertain the impact of sex on GI motor activity across multiple
variations of the EAE model.
In addition to the use of different EAE models for investigation into the greater translatable
potential effects of sex on motor activity, this study also spurred many questions about the possible
effects of estrogen on EAE in the GI tract. Previous studies have suggested that elevated levels of
estrogen can reduce EAE symptomology (Haghmorad et al., 2016; Polanczyk et al., 2003) and that
the position within the estrous cycle can have an impact on EAE presentation and neurological
motor impairment (Rahn et al., 2014). However, very little research has specifically examined the
implications of estrogen on GI motility and symptomology in the GI tract of EAE mice. Therefore,
future aims of this research might attempt to quantify estrogen levels during the EAE experimental
period to potentially correlate estrogen expression with the GI symptomology time line. Similarly,
it might be beneficial to study mice with synchronized estrous cycles in order to potentially negate
estrous cycle derived variability in the EAE model. This line of inquiry would therefore allow for
a better understanding of the possible differences in peak GI dysmotility time points noted between
female and male mice.
Along these lines it is also suggested that a more thorough molecular examination into the
potential sex derived GI dysmotility peak onset times be investigated. Previous work in the Mawe
lab has indicated that the GI dysfunction seen in EAE mice is B cell mediated and involves the
targeting of autoantibodies (Spear et al., 2018). In this sense, future research might aim to examine
if there are any differences in the circulation of cytokine factors, which are involved in
inflammation, or B cell maturation between female and male mice that might account for the
difference in onset of peak GI dysfunction between sexes.
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